Diurnal variation of cisplatin-induced renal toxicity in ICR mice.

Chronotoxicity Circadian rhythm Cisplatin Nephrotoxicity Side effect

Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
13 Jun 2024
Historique:
received: 10 06 2024
revised: 12 06 2024
accepted: 12 06 2024
medline: 16 6 2024
pubmed: 16 6 2024
entrez: 15 6 2024
Statut: aheadofprint

Résumé

Cisplatin (CDDP) is a platinum-based anticancer drug widely prescribed for its effectiveness in treating various forms of cancer. However, its major side effect is nephrotoxicity. Although several methods have been developed to mitigate CDDP-induced nephrotoxicity, an optimal approach has yet to be established. This study aimed to investigate the "chronotoxicity" of CDDP as a potential strategy to reduce its side effects. Male ICR mice were treated with CDDP (20 mg/kg, intraperitoneal injection, one shot) at zeitgeber time (ZT) 2 or ZT14 (light or dark phase). After 72 h, we collected plasma and kidney and evaluated several markers. We found that body weight change between ZT2 and ZT14 by CDDP was comparable. In contrast, many toxicological factors, such as plasma blood urine nitrogen, plasma creatinine, renal oxidative stress (malondialdehyde), DNA damage (γH2AX), acute kidney injury biomarker (KIM-1), and inflammation (Tnfα), were significantly induced at ZT14 compared to than that of ZT2. Our present data suggested that chronotoxicology might provide beneficial information on the importance of administration timings for toxic evaluations and unacceptable side effects.

Identifiants

pubmed: 38878759
pii: S0006-291X(24)00802-7
doi: 10.1016/j.bbrc.2024.150266
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

150266

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Sarah Tominaga (S)

Graduate School of Pharmaceutical Sciences, Kinjo Gakuin University, 2-1723 Omori, Moriyamaku, Nagoya, Aichi, 463-8521, Japan; Department of Neurotoxicology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.

Hiroki Yoshioka (H)

Faculty of Pharmacy, Gifu University of Medical Science, 4-3-3 Nijigaoka, Kani, Gifu, 509-0293, Japan; Department of Hygiene, Kitasato University, School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan; College of Pharmacy, Kinjo Gakuin University, 2-1723 Omori, Moriyamaku, Nagoya, Aichi, 463-8521, Japan. Electronic address: hyoshioka@u-gifu-ms.ac.jp.

Tatsuya Hasegawa (T)

Department of Environmental Biochemistry, Mount Fuji Research Institute, 5597-1 Kamiyoshidakenmarubi, Fujiyoshida, Yamanashi, 403-0005, Japan.

Masumi Suzui (M)

Faculty of Pharmacy, Gifu University of Medical Science, 4-3-3 Nijigaoka, Kani, Gifu, 509-0293, Japan.

Maeda Tohru (M)

Graduate School of Pharmaceutical Sciences, Kinjo Gakuin University, 2-1723 Omori, Moriyamaku, Nagoya, Aichi, 463-8521, Japan; College of Pharmacy, Kinjo Gakuin University, 2-1723 Omori, Moriyamaku, Nagoya, Aichi, 463-8521, Japan.

Nobuhiko Miura (N)

Department of Health Science, Yokohama University of Pharmacy, 601 Matano-cho, Totsuka-ku, Yokohama, Kanagawa, 245-2006, Japan. Electronic address: nobuhiko.miura@yok.hamayaku.ac.jp.

Classifications MeSH